Adverse effects of antiretroviral therapy for HIV infection

CMAJ. Canadian Medical Association Journal

Volumn 170, Issue 2, 2004, Pages 229-238

  Montessori, Valentina ^a,b,c   Press, Natasha ^a,b   Harris, Marianne ^a,b   Akagi, Linda ^a   Montaner, Julio S G ^a,b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ALOPECIA; ANEMIA; ARTHRALGIA; BLEEDING; BONE NECROSIS; CARDIOMYOPATHY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DROWSINESS; DRUG COMBINATION; DRUG ERUPTION; DYSLIPIDEMIA; FATTY LIVER; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GOUT; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IATROGENIC DISEASE; INCIDENCE; INGROWN NAIL; INSULIN RESISTANCE; LACTIC ACIDOSIS; LEUKOPENIA; LIPODYSTROPHY; LIVER DISEASE; LIVER TOXICITY; LYMPHOCYTE COUNT; MALAISE; MALE; METABOLIC DISORDER; METHODOLOGY; MITOCHONDRIAL TOXICITY; MORTALITY; MOUTH ULCER; MYALGIA; NAUSEA; NEPHROLITHIASIS; NEUROTOXICITY; NEUTROPENIA; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SIDE EFFECT; SKIN DISEASE; SURVIVAL; T LYMPHOCYTE; VIRUS LOAD;

EID: 1642578228     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhre J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-60.
2. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. AIDS Cohort Study Investigators. JAMA 1998;280:1497-503.
3. Hogg RS, Yip B, Kully C, Craib KJP, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999;160(5):659-65.
4. d'Arminio Monforte A, Lepri AC, Rezza G, Pezzotti P, Antinori A, Phillips AN, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.C.O.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients. AIDS 2000;14:499-507.
5. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999;131:81-7.
6. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.
7. Lewis W, Dalakis MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995;1:417-21.
8. Lai KK, Gang DL, Zawacki JK, Cooley TP. Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddl). Ann Intern Med 1991;115:283-4.
9. Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cotte L, Chevallier M, et al. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med 1994;235:367-71.
10. Olano JP, Borucki MJ, Wen JW. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine. Clin Infect Dis 1995;21: 973-6.
11. Sundar K, Suarez M, Banogon PE, Shapiro JP. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit Care Med 1997;25:1425-30.
12. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. AIDS 1997;11:1294-6.
13. Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44.
14. Chariot P, Drogou I, de Lacroix-Szmania I, Eliezer-Vanerot MC, Chazaud B, Lombes A, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol 1999;30:156-60.
15. Fortgang I, Belitsos P, Chaisson R, Moore R. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analogue antiretroviral therapy. Am J Gastroenterol 1995;90:1433-6.
16. Antoniou T, Weisdorf T, Gough K. Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion. CMAJ 2003;168(2):195-8.
17. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000;31(1):162-6.
18. Harris M, Tesiorowski A, Chan K, Hogg R, Rosenberg R, Chan Yan C, et al. Lactic acidosis complicating antiretroviral therapy: frequency and correlates [abstract 36]. Antivir Ther 2000;5(Suppl 2):31.
19. Tesiorowski AM, Harris M, Chan KJ, Thompson CR, Montaner JSG. Anaerobic threshold and random venous lactate levels among HIV-positive patients on antiretroviral therapy. J Acquir Immune Defic Syndr 2002;31(2):250-1.
20. Delgado J, Harris M, Tesiorowski A, Montaner JSG. Symptomatic elevations of lactic acid and their response to treatment manipulation in HIV infected individuals - a case series. Clin Infect Dis 2001;33:2072-4.
21. Lonergan JT, Havlir D, Behling C, Pfander H, Hassenein T, Mathews WC. Hyperlactatemia in 20 patients receiving NRTI combination regimens [poster, session 9]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30 to 2000 Feb 2; San Francisco.
22. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, et al. Chronic hyperlactatemia in FDV-infected patients taking antiretroviral therapy. AIDS 2001;15:717-23.
23. Medina DJ, Tsai CH, Hsiung GD, Cheng YC. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother 1994;38(8):1824-8.
24. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38:2743-9.
25. Johns D. The other human genome: mitochondrial DNA and disease. Nat Med 1996;2:1065-8.
26. Plymale DR, Tang DS, Comardelle AM, Fermin CD, Lewis DE, Garry RF. Both necrosis and apoptosis contribute to HIV-1 induced killing of CD4 cells. AIDS 1999;13:1827-39.
27. Cote H, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, et al. Application of a novel assay to monitor peripheral blood mitochondrial DNA levels in HIV-infected patients on combination antiretroviral therapy. N Engl J Med 2002;346(11):811-20.
28. Emmett M, Narins RG. Clinical use of the anion gap. Medicine (Baltimore) 1977;56:38-54.
29. Gabow PA. Disorders associated with an altered anion gap. Kidney Int 1985;27:472-83.
30. Gabow PA, Kaehny WD, Fennessey PV, Goodman SI, Gross PA, Schrier RW, et al. Diagnostic importance of an increased serum anion gap. N Engl J Med 1980;303:854-8.
31. Winter SD, Pearson R, Gabow PA, Schultz AL, Lepoff RB. The fell of the serum anion gap. Arch Intern Med 1990;150:311-3.
32. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 1998;352:291-2.
33. Luzzati R, Del Bravo P, Di Perri G, Luzzani A, Concia E. Riboflavine and severe lactic acidosis. Lancet 1999;353:901-2.
34. Church J, Mitchell W, Gonzalez-Gomez I, Boles R, Wetzel R, Vu T. Near-fatal metabolic acidosis, liver failure, and mitochondrial (mt) DNA depletion in an HIV-infected child treated with combination antiretroviral therapy (ART) [abstract 58]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30 to 2000 Feb 2; San Francisco.
35. Schramm C, Wanitschke R, Galle PR. Thiamine for the treatment of nucleoside analogue-induced severe lactic acidosis. Eur J Anaesthesiol 1999;16:733-5.
36. Brinkman K, Vrouenraets S, Kauffmann R, Weigel H, Frissen J. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS 2000;14:2801-2.
37. Przyrembel H. Therapy of mitochondrial disorders. J Inherit Metab Dis 1987; 10 (Suppl 1): 129-46.
38. Campos Y, Huertas R, Lorenzo G, Bautista J, Gutierrez E, Aparicio M, et al. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 1993;43:884-90.
39. 10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993;43:884-90.
40. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000;283 (1):74-80.
41. den Brinker M, Wit FNM, Wetheim-van Dillen PME, Jurriaans S, Weel J, van Leeuwen R, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14(18):2895-902.
42. Dieterich DT. Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. Am J Med 1999;107(6B):79S-84S.
43. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A, et al. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001;34(2):283-7.
44. Reisler R, Liou S, Servoss JC, Robbins G, Theodore D, Murphy R, et al. Incidence of hepatotoxicity and mortality in 21 adult antiretroviral treatment trials [abstract 43]. ACTG Liver Diseases Focus Group. 1st International AIDS Society Conference on HIV Pathogenesis and Treatment; 2001 Jul 8-11; Buenos Aires.
45. Sulkowski, M, Mehta S, Thomas D, Moore R. Hepatotoxicity associated with NNRTI use: role of drugs and chronic hepatitis [abstract 618]. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4-8; Chicago.
46. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Morbid Mortal Wkly Rep 2001;49(51):1153-6.
47. Lee ECC, Walmsley S, Fantus IG. New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review. CMAJ 1999;161(2):161-4.
48. Dube MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis 2000;31:1467-75.
49. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
50. Press N, Montessori VC, Bai T, Montaner JSG. Respiratory failure due to protease inhibitor related lipodystrophy in an HIV patient with compromised lung function. Can Respir J 2001;8(4):279-82.
51. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999;13:1359-67.
52. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-32.
53. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus. Lancet 1999;353:2893-9.
54. Schwenk A, Breur JP, Kremer G, Romer K, Bethe U, Franzen C, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study. Eur J Med Res 2000;5(10):443-8.
55. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357(9256):592-8.
56. Friis-Moller N, Weber R, D'Arminio Monforte A, El-Sadr W, Reiss P, Dabis F, et al. Exposure to HAART is associated with an increased risk of myocardial infarction: the DAD Study [abstract 130]. 10th Conference on Retroviruses and Opportunistic Infections, 2003 Feb 10-14; Boston.
57. Klein D, Hurley L. Hospitalizations for coronary heart disease and myocardial infarction among HIV+ patients in the HAART era [abstract 696-T]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle.
58. Holmberg S, Moorman, A, Tong, T, Ward D, Wood K, Greenberg AE, et al, for the HIV Outpatient Study (HOPS) Investigators. Protease inhibitor use and adverse cardiovascular outcomes in ambulatory HIV patients [abstract 698-T]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle.
59. Bozzette SA, Ake C, Carpenter A, Bommakanty U, Leung V, Tam H, et al. Cardio and cerebrovascular outcomes with changing process of anti-HIV therapy in 36,766 US veterans [abstract LB-9]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle.
60. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;351:1881-3.
61. Hollmig KA, Beck SB, Doll DC. Severe bleeding complications in HIV-positive haemophiliac patients treated with protease inhibitors. Eur J Med Res 2001; 6(3):112-4.
62. Kodoth S, Bakashi S, Scimeca P, Black K, Pahwa S. Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac. AIDS Patient Care STDS 2001;15(7):347-52.
63. Wilde JT, Lee CA, Collins P, Giangrande PLF, Winter M, Shiach CR. Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders. Br J Haematol 1999;107:556-9.
64. Gerster JC, Camus JP, Chave JP, Koeger AC, Rappoport G. Multiple site avascular necrosis in HIV infected patients. J Rheumatol 1991;18(2):300-2.
65. Scribner AN, Troia-Cancio PV, Cox BA, Marcantonio D, Hamid F, Keiser P, et al. Osteonecrosis in HIV: a case-control study. J Acquir Immune Defic Syndr 2000;25(1):19-25.
66. Roudiere L, Viard JP. Osteonecrosis of the hip, lipodystrophy and antiretroviral treatment [letter]. AIDS 2000;14(13):2056.
67. Khan AA, Brown JP, Kendler DL, Leslie WD, Lentle BC, Lewiecki EM, et al. The 2002 Canadian bone densitometry recommendations: take-home messages. CMAJ 2002;167(10):1141-5.
68. Paton NI, Macallan DC, Griffin GE, Pazianas M. Bone mineral density in patients with human immunodeficiency virus infection. Calcif Tissue Int 1997; 61:30-2.
69. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000;14:F63-7.
70. Carr A, Eisman JA, Miller J, Cooper DA. Lactic acidemia is associated with spinal osteopenia in HIV-infected men [abstract 631]. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4-8; Chicago.
71. Wang M, Teitelbaum SL, Tebas P, Powderly WG, Ross FP. Indinavir inhibits bone formation while ritonavir inhibits osteoclast differentiation and function [abstract 541]. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4-8; Chicago.
72. Dusso A, Vidal M, Powderly WG, Yarasheski KE, Tebas P. Protease inhibitors inhibit in vitro conversion on 25(OH)-vitamin D to 1,25(OH)2-vitamin D [abstract 030]. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy; 2000 Sep 13-15; Toronto.
73. Brown JP, Josse RG, for the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2022;167(10 suppl):S1-34.
74. Fagot JP, Mockenhaupt M, Bouwes-Bavnick JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001;15:1843-8.
75. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002;137(5 pt 2):381-433.
76. Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002;24 (10):1502-14.
77. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis 2002;34 (8):1137-42.
78. Powderly WG. The strategy of antiretroviral switch studies - a review [abstract 1375]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto.
79. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12.
80. Fodor JG, Frolich JJ, Genest JJG Jr, McPherson PR, for Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management and treatment of dyslipidemia: report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 2000;162(10):1441-7.
81. Fung MA, Frohlich JJ. Common problems in the management of hypertriglyceridemia. CMAJ 2002;167(11):1261-6.
82. Dube MP, Sprecher D, Henry WK, Aberg JA, Torriani FJ, Hodis HN, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in HIV-infected adults receiving antiretroviral therapy. Recommendations of the Adult ACTG Cardiovascular Disease Focus Group. Clin Infect Dis 2000;31:1216-24.
83. Ponce-de-Leon S, Iglesias M, Ceballos J, Ostrosky-Zeichner L. Liposuction for protease-inhibitor-associated lipodystrophy [letter]. Lancet 1999;353:1244.